Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

por Corbin, Amie S., Agarwal, Anupriya, Loriaux, Marc, Cortes, Jorge, Deininger, Michael W., Druker, Brian J.
Publicado em 2010

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

por Corbin, Amie S., Agarwal, Anupriya, Loriaux, Marc, Cortes, Jorge, Deininger, Michael W., Druker, Brian J.
Publicado em 2011

A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice

por Johnson, Kara J., Griswold, Ian J., O'Hare, Thomas, Corbin, Amie S., Loriaux, Marc, Deininger, Michael W., Druker, Brian J.
Publicado em 2009

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

por Agarwal, Anupriya, Bumm, Thomas G. P., Corbin, Amie S., O'Hare, Thomas, Loriaux, Marc, VanDyke, Jonathan, Willis, Stephanie G., Deininger, Jutta, Nakayama, Keiichi I., Druker, Brian J., Deininger, Michael W.
Publicado em 2008

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

por Tyner, Jeffrey W., Walters, Denise K., Willis, Stephanie G., Luttropp, Mary, Oost, Jason, Loriaux, Marc, Erickson, Heidi, Corbin, Amie S., O'Hare, Thomas, Heinrich, Michael C., Deininger, Michael W., Druker, Brian J.
Publicado em 2008

The BCR-ABL(35INS) insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

por O'Hare, Thomas, Zabriskie, Matthew S., Eide, Christopher A., Agarwal, Anupriya, Adrian, Lauren T., You, Huihong, Corbin, Amie S., Yang, Fei, Press, Richard D., Rivera, Victor M., Toplin, Julie, Wong, Stephane, Deininger, Michael W., Druker, Brian J.
Publicado em 2011

SGX393 inhibits the CML mutant Bcr-Abl(T315I) and preempts in vitro resistance when combined with nilotinib or dasatinib

por O'Hare, Thomas, Eide, Christopher A., Tyner, Jeffrey W., Corbin, Amie S., Wong, Matthew J., Buchanan, Sean, Holme, Kevin, Jessen, Katayoun A., Tang, Crystal, Lewis, Hal A., Romero, Richard D., Burley, Stephen K., Deininger, Michael W.
Publicado em 2008

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors

por Corbin, Amie S., O’Hare, Thomas, Gu, Zhimin, Kraft, Ira L., Eiring, Anna M., Khorashad, Jamshid S., Pomicter, Anthony D., Zhang, Tian Y., Eide, Christopher A., Manley, Paul W., Cortes, Jorge E., Druker, Brian J., Deininger, Michael W.
Publicado em 2013

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

por Griswold, Ian J., MacPartlin, Mary, Bumm, Thomas, Goss, Valerie L., O'Hare, Thomas, Lee, Kimberly A., Corbin, Amie S., Stoffregen, Eric P., Smith, Caitlyn, Johnson, Kara, Moseson, Erika M., Wood, Lisa J., Polakiewicz, Roberto D., Druker, Brian J., Deininger, Michael W.
Publicado em 2006

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

por O’Hare, Thomas, Shakespeare, William C., Zhu, Xiaotian, Eide, Christopher A., Rivera, Victor M., Wang, Frank, Adrian, Lauren T., Zhou, Tianjun, Huang, Wei-Sheng, Xu, Qihong, Metcalf, Chester A., Tyner, Jeffrey W., Loriaux, Marc M., Corbin, Amie S., Wardwell, Scott, Ning, Yaoyu, Keats, Jeffrey A., Wang, Yihan, Sundaramoorthi, Raji, Thomas, Mathew, Zhou, Dong, Snodgrass, Joseph, Commodore, Lois, Sawyer, Tomi K., Dalgarno, David C., Deininger, Michael W.N., Druker, Brian J., Clackson, Tim
Publicado em 2009